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 INTRODUCTION
Antiphospholipid syndrome is a systemic autoim-
mune disease characterized by the presence of circulat-
ing antiphospholipid antibodies (aPL). The first inter-
national consensus statement on diagnostic criteria of 
APS was developed in 1998 in Japan and was updated 
in 2006. The diagnostic criteria include existence of 
these antibodies and clinical criteria such as thrombotic 
events in any organ and/or pregnancy morbidity1. It 
can occur as a primary disease or in association with 
other autoimmune diseases, the most frequent being 
Systemic Lupus Erythematosus (SLE). About 30 to 40% 
of SLE patients have circulating aPL and about half of 
them will develop APS in a 10 to 20 year follow -up2. 
Both can affect the kidney independently or simultane-
ously, making the differential diagnosis between inflam-
matory and thrombotic damage a challenge, as it 
impacts the way these patients are treated.
APS has been associated with various forms of kidney 
injury, including large renal vessel thrombosis and renal 
artery stenosis, but the advent of renal biopsies and renal 
histopathology has allowed the description and 
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characterization of the microscopic renal damage by the 
aPL. The spectrum of these alterations, which are associ-
ated with deleterious impact on kidney function, has been 
defined as antiphospholipid nephropathy (APSN). It refers 
to the ischaemic damage (without inflammatory damage) 
of the renal parenchyma caused by thrombotic micro-
angiopathy and proliferative and fibrotic lesions of the 
intra -renal vessels without inflammatory damage2,3.
The clinical manifestations are unspecific and can 
range from hypertension, reduced kidney function, 
proteinuria usually <1.5g/day and microscopic haema-
turia to acute kidney injury. APSN prevalence in primary 
APS is estimated to be 2.7% to 9% though it is probably 
underestimated. In secondary APS associated with SLE, 
it can range from 9% to 40% due to the fact that biopsies 
are preformed more consistently in this group and it 
can coexist with lupus nephritis4.
Moreover, as few kidney biopsies of APS patients 
are performed, due to the fact that these patients fre-
quently have low platelet counts and are anticoagu-
lated, other kinds of renal manifestations associated 
with APS besides APSN, namely glomerulopathies have 
not been well characterized.
The diagnosis of APSN and APS -associated glomeru-
lopathies is challenging, particularly in patients with 
diagnosis of SLE, and requires renal biopsy.
 CASE REPORT
A 39 -year -old Caucasian woman, with APS diagnosis 
two years prior, was referred to a nephrology consulta-
tion for proteinuria and microscopic haematuria with 
preserved renal function. She had a history of deep 
venous thrombosis of her left leg at the age of 22 and 
intermittent polyarthralgia complaints of distal joints 
from the age of 24 to the present.
Due to her medical history, she started attending 
rheumatology consultations when she was 29 years 
old. She was prescribed aspirin and corticoids, but did 
not comply. Four years later a laboratory analysis 
detected B2 -glicoprotein, anti -cardiolipin (IgG and IgM) 
and anti -SLC70 antibodies, lupic anticoagulant and 
ANAs without the presence of anti -Double Stranded 
DNA (DsDNA) antibodies. Due to patient’s complaints 
of migraine, an MRI was performed, which detected a 
“left hemisphere deep vascular ischaemic lesion of the 
deep branches of the left cerebral anterior artery”.
At the age of 39, she was referred to a nephrology 
consultation. Of her laboratory evaluation, we empha-
size urine analysis with proteinuria (++) and haematuria 
(++), measured 24h proteinuria of 1.7–2.4g/day, sCr 
0.7mg/dL and identified B2 -glicoprotein, anti -cardiolipin 
and lupic anticoagulant antibodies. The protein elec-
trophoretic pattern was within normal range and 
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Figure 1
Hematoxylin & eosin, 20x. Glomerular enlargement with mesangial 
expansion, essentially peri ‑hilar, capillary wall thickening and hya‑
line thrombus (back arrow)
 
Figure 2
Silver stain, 20x. Rearrangement of the basal membrane around 
multiple inclusions (red arrow); discrete double contours were 
observed in two glomeruli (red arrow) 
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immunoglobulin and serum light free chain had no 
relevant alterations.
The physical exam did not reveal any relevant abnor-
malities such as hypertension, oedema or neurologic 
deficits. The laboratory workup showed urine albumin-
-creatinine ratio of 2000mg/g, normal complement 
measurements (C3, C4, CH50), negative DsDNA and 
the presence of ANAs and anti -centromere antibodies. 
HIV, HBV and HCV serologies were negative. The 
remaining results were similar. A renal biopsy was pre-
formed and the patient was discharged and treated 
with ACE inhibitors, hydroxychloroquine and oral anti-
coagulants (dabigatran).
Two weeks later the renal biopsy report described as 
part of the light microscopy exam membranous glomeru-
lonephritis, most likely secondary, with enlarged glo-
meruli, global thickening of the capillary walls and a slight 
segmental expansion of the mesangial matrix without 
a significant cellularity increase (Fig.1). The silver stain 
showed countless inclusions (Fig.2). It also described 
slight double contours on two glomeruli and some hya-
line thrombi suggesting chronic ischaemia, which can 
be present in APS/APSN. The immunofluorescence exam 
showed IgG, C3 and light chain lambda and kappa uni-
versal granular deposits (capillary wall and mesangium), 
with absence of IgM, IgA, C1, C4 and fibrin. Electron 
microscopy (Fig. 3 A and 3B) showed an atypical 
membranous pattern with mesangial, subepithelial and 
intramembranous granular deposits and a capillary 
thrombus probably in probable association with APS.
Since her discharge, the patient has not returned 
for follow -up appointments.
 DISCUSSION
This case report illustrates a complex clinical and 
anatomopathological case of a 39 -year -old woman with 
a previous APS diagnosis who presented with unspecific 
manifestations of proteinuria and microscopic haema-
turia with preserved renal function.
The patient had a definite APS diagnosis as she presented 
with persistent aPL longer than 12 weeks, a venous throm-
bosis episode and a probable arterial cerebral ischaemic 
lesion documented on the MRI. The hypothesis of SLE in 
association with APS was suspected based on the presence 
of three of the eleven American College of Rheumatology 
(ACR) criteria. These included immunological disorder with 
the presence of anti -cardiolipin antibodies, a positive test 
for antinuclear antibodies (ANA) and persistent proteinuria. 
Although there was a description of intermittent polyarthal-
gia, the patient did not present with erythema or swelling 
of the joints consistent with a definite diagnosis of 
Atypical renal presentation of antiphospholipid syndrome
Figure 3
Electron Microscopy A. rearrangement of the capillary wall, with reactive basal membrane surrounding intramembranous granular deposits. 
There is obstruction of one of the capillary lumens with a thrombus; B. subepithelial deposits
A B
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non -erosive arthritis, which would be the fourth criteria 
necessary for definite SLE diagnosis according to the ACR 
criteria. According to the Systemic Lupus International Col-
laborating Clinics group which reviewed and validated the 
ACR SLE classification criteria in 2012, to establish the diag-
nosis of SLE the patient has to meet four of the eleven ACR 
or lupus nephritis criteria documented on a renal biopsy 
with ANA or anti -dsDNA antibodies5,6. Considering that 
the patient only met three ACR criteria, including persistent 
proteinuria, and there was no evidence of other important 
aspects such as constitutional symptoms, presence of 
DsDNA antibodies or low C3 or C4, a renal biopsy was 
important not only to document renal manifestations of 
APS but also to assess for lupus nephritis7.
The anatomopathological exam was interpreted as 
atypical secondary membranous glomerulopathy and 
thrombotic microangiopathy with thrombi probably 
associated with ASP/ASPN. The presence of mesangial 
deposits on electron microscopy made the diagnosis 
of primary membranous glomerulonephritis less likely, 
although measurements of anti -phospholipase A2 
receptor antibodies are crucial to definitely exclude 
this diagnosis. It also did not fulfill diagnostic criteria 
for type V membranous lupus nephritis due to the 
absence of hypercelularity and C1q or other immuno-
globulin deposits on immunofluorescence exam8,9. 
Also, she scored 0 on the point system used to deter-
mine both lupic nephritis activity and chronicity indices. 
Association of membranous glomerulonephritis with 
APS is rare, but was described in a series of 29 biopsies 
performed on APS patients in two university hospitals 
in Paris in 20033. Of these 29 cases, 69% revealed vas-
cular characteristics of APSN and 31% pathological 
findings other than APSN. In this last group, the most 
frequent was membranous nephropathy, representing 
33% within this group and 10% of the total10. Other 
causes of secondary membranous nephropathy, such 
as malignancies and other autoimmune conditions, 
must also be excluded in this patient’s follow -up.
Another challenging aspect of the anatomopathologi-
cal exam is the presence of few subtle double contours 
which in association with peri -hilar capillary wall mesan-
gial expansion was interpreted as being chronic ischae-
mic alterations, but poses the hypothesis of a mem-
branoproliferative glomerulonephritis. This hypothesis 
appeared less probable due to the absence of suben-
dothelial deposits on electron microscopy9,10.
The initial treatment with hydroxychloroquine and 
ACE inhibitors took into account the possible SLE diag-
nosis in association with subnephrotic proteinuria in 
an otherwise asymptomatic patient. However the 
authors concluded that based on the biopsy findings, 
the patient did not meet criteria for a definite SLE. As 
the patient did not return for follow -up appointments, 
the treatment and its outcome has yet to be assessed.
For the APS diagnosis, this patient started treatment 
with oral anticoagulants. Although the approved anti-
coagulants for this condition consist of vitamin K antag-
onists, preliminary trials supporting the use of new oral 
anticoagulants have recently been reported3,11. Due 
to this patient previously showing non -compliance with 
her medication, dabigatran was decided on as treat-
ment since it has proven to be safe in patients with 
venous thrombosis history, without the need for labo-
ratory monitoring. The patient was informed and 
agreed to this treatment.
This case illustrates the complexity of renal mani-
festations of APS and demonstrates the importance of 
renal biopsy and anatomopathological exam, including 
electron microscopy, to better characterize these 
patients.
Disclosure of potential conflicts of interest: none declared.
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